Breakout Ventures

EnPlusOne Biosciences specializes in developing innovative solutions for RNA therapeutics through its advanced synthesis platform. The company focuses on enzymatic-based RNA synthesis, which aims to address the limitations of traditional chemical synthesis methods. By tackling systemic challenges related to scaled production and access to novel therapeutic modifications, EnPlusOne enables the sustainable manufacturing of therapeutic RNA at a commercial scale. This approach positions the company to contribute significantly to the growing field of RNA-based therapeutics.

Copernic Catalysts is a company focused on developing sustainable chemical catalysts and processes aimed at reducing the carbon footprint across various industries. The firm designs innovative zero- and low-carbon technologies that align with the current economic landscape of the chemical sector. Its advanced catalysts and processes support the production of sustainable chemicals and synthetic fuels, helping clients enhance energy efficiency, lower production costs, and access affordable zero-carbon chemicals. Through these efforts, Copernic Catalysts contributes to a more sustainable future in chemical manufacturing.

Passkey Therapeutics is pioneering a new class of medicines, Synergistic Multifunctional Therapeutics (SMThs). It is designed to address complex diseases by targeting rare combinations of proteins that work together.

CytoVale, Inc. is a medical technology company based in San Francisco, California, established in 2012. The company specializes in developing biomarkers that leverage the mechanical properties of individual cells, a field known as mechanomics. By utilizing microfluidics technology, CytoVale can efficiently route and physically probe single cells to measure multiple biomarkers simultaneously. This innovative approach aims to enhance early detection of immune-mediated diseases, particularly sepsis, thereby improving patient outcomes and reducing treatment costs. CytoVale's integration of cell mechanics with machine learning positions it at the forefront of revolutionizing diagnostic practices in healthcare.

TFC Therapeutics is a biotechnology company focused on developing innovative biologics aimed at addressing key drivers of cancer recurrence and metastasis. The company’s technology utilizes monoclonal antibodies that specifically bind to receptors on the surface of tumor-initiating cells (TMH cells). This binding action activates the immune system to target and destroy these cells, offering the potential for new cancer treatments. By concentrating on the elimination of TMH cells, TFC Therapeutics seeks to provide effective solutions for improving patient outcomes in cancer care.

A-Alpha Bio, Inc. is a biotechnology company based in Seattle, Washington, established in 2017. The company specializes in synthetic biology, offering a platform known as AlphaSeq, which assists pharmaceutical companies in the development of drugs that interact with multiple targets. A-Alpha Bio provides cell-based tools for high-throughput and quantitative measurements of protein interactions, facilitating target discovery, library screening, and preclinical drug characterization. Its proprietary technology enables the mapping of protein-protein interactions at a large scale, allowing for the identification and quantification of interactions among thousands of protein pairs simultaneously. By delivering detailed maps of these interactions, A-Alpha Bio helps researchers identify potential drug targets and understand disease mechanisms, thereby streamlining the therapeutic discovery process and improving the efficiency of drug development. The company comprises a team of experts in synthetic biology, structural biology, and next-generation sequencing, focused on overcoming challenges in the drug development pipeline.

Parallel Bio is a biotechnology company focused on transforming the discovery and development of immunotherapies. The company utilizes a platform that integrates advanced human immune organoids with computational techniques to provide valuable insights into human health and disease. By leveraging these innovative tools, Parallel Bio aims to overcome existing barriers in drug development, facilitating quicker pathways to effective treatments for various diseases, including the advancement of immunotherapies, cell therapies, antibody therapies, and vaccines. This approach enhances the ability of medical professionals to understand and address complex health challenges.

EnPlusOne Biosciences specializes in developing innovative solutions for RNA therapeutics through its advanced synthesis platform. The company focuses on enzymatic-based RNA synthesis, which aims to address the limitations of traditional chemical synthesis methods. By tackling systemic challenges related to scaled production and access to novel therapeutic modifications, EnPlusOne enables the sustainable manufacturing of therapeutic RNA at a commercial scale. This approach positions the company to contribute significantly to the growing field of RNA-based therapeutics.

Canaery is focused on developing a neural interface that digitizes the sense of smell to analyze the scent fingerprints of objects. This innovative technology is designed to identify hazardous compounds at critical locations such as ports and inspection points. By utilizing this neurotech device, clients can detect not only the presence of dangerous substances but also gain insights into the nature and condition of the objects being inspected.

Twelve is a company that focuses on providing innovative cashless payment solutions tailored for various industries, including sports, events, catering, and museums. The company has developed a user-friendly online cash register and payment system designed primarily for sports clubs, which facilitates point-of-sale transactions and supports digital pricing along with debit and credit payments. Twelve aims to enhance the payment experience for clients by offering software modules, ordering solutions, and communication tools, thereby helping entrepreneurs and organizers achieve greater success in their initiatives.

Twelve, formerly known as Opus 12, is a Berkeley, California-based company that specializes in recycling carbon dioxide emissions into valuable chemicals and fuels. Founded in 2015, the company has developed innovative technology that can be integrated with any source of CO₂ emissions. By utilizing only water and electricity as inputs, Twelve transforms captured carbon dioxide into essential products such as methane, ethylene, and ethanol. The firm aims to provide a cost-competitive alternative to petroleum-derived chemicals and fuels, thereby addressing carbon emissions while simultaneously creating economically viable solutions.

Surf Bio is a preclinical biopharmaceutical company focused on developing innovative therapeutic solutions using a novel biotechnology platform. This platform centers around a next-generation surfactant designed to enhance drug effectiveness for a variety of medical conditions, including diabetes, oncology, infectious diseases, and gene therapy. By improving therapeutic applications, Surf Bio aims to provide healthcare organizations worldwide with access to new and more effective treatments for patients facing critical health issues.

Phantom Neuro is a neurotechnology company focused on developing innovative muscle-machine interfaces to enhance robotic limb rehabilitation. By integrating neurotechnology with robotic systems, Phantom Neuro aims to improve mobility for users through precise control of robotic limbs, facilitating more natural movement and enhancing user experiences. The company employs a minimally invasive approach, which allows for effective rehabilitation solutions that address the needs of individuals with mobility challenges. Additionally, Phantom Neuro explores various applications of its technologies within the broader field of assistive robotics, striving to provide valuable tools that help patients with limb deficits regain control over their lives and improve their overall quality of life.

Circuit Clinical is an integrated research organization that facilitates participation in clinical research for patients and healthcare providers. Founded in 2015, it emerged from the experiences of a physician who recognized the importance of trust in the clinical research process. Circuit Clinical focuses on enhancing physician and participant engagement, leveraging HIPAA and FDA-compliant Electronic Medical Record (EMR) reviews to identify motivated participants. The organization provides a suite of technology products designed to improve the clinical research experience for both participants and physicians. By connecting a network of over one million patients with community physicians and research sponsors, Circuit Clinical aims to improve site quality and patient safety, making clinical research more accessible and navigable for all involved.

ZymoChem, Inc. is a biotechnology company based in Emeryville, California, founded in 2013. It specializes in the development of eco-friendly chemicals and bioprocesses using engineered microbes to convert renewable feedstocks, such as sugars, into industrial chemicals. The company’s bio-manufacturing platform aims to produce bio-based materials while minimizing carbon emissions during production, thereby supporting a carbon-efficient economy. By establishing cost-effective bioprocesses and novel biosynthetic pathways, ZymoChem enables clients to reduce production costs and enhance their competitiveness in the market. Through its innovative approach, the company contributes to sustainable manufacturing practices and the advancement of a real-zero economy.

Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as manycancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on research, the company is designing a portfolio of drug candidates to treat the right patients at the right time.

Twelve, formerly known as Opus 12, is a Berkeley, California-based company that specializes in recycling carbon dioxide emissions into valuable chemicals and fuels. Founded in 2015, the company has developed innovative technology that can be integrated with any source of CO₂ emissions. By utilizing only water and electricity as inputs, Twelve transforms captured carbon dioxide into essential products such as methane, ethylene, and ethanol. The firm aims to provide a cost-competitive alternative to petroleum-derived chemicals and fuels, thereby addressing carbon emissions while simultaneously creating economically viable solutions.

Circuit Clinical is an integrated research organization that facilitates participation in clinical research for patients and healthcare providers. Founded in 2015, it emerged from the experiences of a physician who recognized the importance of trust in the clinical research process. Circuit Clinical focuses on enhancing physician and participant engagement, leveraging HIPAA and FDA-compliant Electronic Medical Record (EMR) reviews to identify motivated participants. The organization provides a suite of technology products designed to improve the clinical research experience for both participants and physicians. By connecting a network of over one million patients with community physicians and research sponsors, Circuit Clinical aims to improve site quality and patient safety, making clinical research more accessible and navigable for all involved.

CytoVale, Inc. is a medical technology company based in San Francisco, California, established in 2012. The company specializes in developing biomarkers that leverage the mechanical properties of individual cells, a field known as mechanomics. By utilizing microfluidics technology, CytoVale can efficiently route and physically probe single cells to measure multiple biomarkers simultaneously. This innovative approach aims to enhance early detection of immune-mediated diseases, particularly sepsis, thereby improving patient outcomes and reducing treatment costs. CytoVale's integration of cell mechanics with machine learning positions it at the forefront of revolutionizing diagnostic practices in healthcare.

Immusoft Corporation is a biotechnology company focused on developing an autologous cell therapy platform aimed at treating a range of human diseases through its proprietary Immune System Programming (ISP) technology. Founded in 2009 and based in Seattle, Washington, Immusoft specializes in modifying the DNA of a patient's immune cells to create biofactories capable of producing gene-encoded medicines, including essential proteins and enzymes that may be missing or defective. The company's innovative approach involves reprogramming B cells, a type of immune cell, which enables them to manufacture and secrete various antibodies. This process not only provides a potential long-term solution for patients but also positions Immusoft at the forefront of biotechnology in addressing rare and infectious diseases.

Checkerspot, Inc. is a biotechnology company based in Berkeley, California, established in 2016. The company specializes in creating performance materials derived from microalgae, focusing on sustainable and high-performance applications. Checkerspot employs advanced techniques in molecular foundry, chemistry, material science, and fabrication technology to develop innovative products, including polyurethanes and textile finish materials. By leveraging the power of biotechnology, Checkerspot aims to expand the range of molecular building blocks available for various industrial applications, providing industries with access to a new generation of sustainable materials.

ShiraTronics, Inc. is a company that specializes in developing and commercializing neuromodulation therapies aimed at treating chronic migraines, a condition that significantly impacts the lives of millions worldwide. Founded in 2018 and headquartered in Ireland, with an additional location in Minneapolis, Minnesota, ShiraTronics is focused on addressing unmet clinical needs in neurology. The company's innovative technologies offer new approaches to effectively alleviate the debilitating effects of migraine headaches, thereby striving to improve the quality of life for those affected by this disabling disorder.

CytoVale, Inc. is a medical technology company based in San Francisco, California, established in 2012. The company specializes in developing biomarkers that leverage the mechanical properties of individual cells, a field known as mechanomics. By utilizing microfluidics technology, CytoVale can efficiently route and physically probe single cells to measure multiple biomarkers simultaneously. This innovative approach aims to enhance early detection of immune-mediated diseases, particularly sepsis, thereby improving patient outcomes and reducing treatment costs. CytoVale's integration of cell mechanics with machine learning positions it at the forefront of revolutionizing diagnostic practices in healthcare.

Curie Co is a life science company dedicated to developing sustainable alternatives to harmful chemicals by engineering enzymes and marine biomaterials. The company focuses on replacing petrochemical-based ingredients with 100% safe and sustainable options derived from recycled marine sources, branded as OceanSafe. Curie Co aims to provide consumers with familiar products available at major retailers like Walmart, Target, and CVS, all while maintaining competitive price points. Their innovative approach enables businesses across various industries to adopt eco-friendly packaging solutions without sacrificing quality or performance. By positioning itself as a trusted supplier of engineered enzymes and biopolymers, Curie Co strives to lead the way in promoting environmentally responsible practices in product development.

Checkerspot, Inc. is a biotechnology company based in Berkeley, California, established in 2016. The company specializes in creating performance materials derived from microalgae, focusing on sustainable and high-performance applications. Checkerspot employs advanced techniques in molecular foundry, chemistry, material science, and fabrication technology to develop innovative products, including polyurethanes and textile finish materials. By leveraging the power of biotechnology, Checkerspot aims to expand the range of molecular building blocks available for various industrial applications, providing industries with access to a new generation of sustainable materials.

Phylagen, Inc. is a data analytics company based in San Francisco that specializes in microbiome data analytics. Founded in 2014, the company employs DNA sequencing and machine learning to analyze complex genetic signatures within the environmental microbiome, transforming this extensive dataset into actionable insights for various industries. Phylagen also develops automated biosensors for indoor microbiome monitoring, which aim to enhance human health and safety by enabling early detection of pathogens, including COVID-19. Additionally, the company's solutions help manage allergy and asthma triggers, ensuring a healthier indoor environment for users.

Immusoft Corporation is a biotechnology company focused on developing an autologous cell therapy platform aimed at treating a range of human diseases through its proprietary Immune System Programming (ISP) technology. Founded in 2009 and based in Seattle, Washington, Immusoft specializes in modifying the DNA of a patient's immune cells to create biofactories capable of producing gene-encoded medicines, including essential proteins and enzymes that may be missing or defective. The company's innovative approach involves reprogramming B cells, a type of immune cell, which enables them to manufacture and secrete various antibodies. This process not only provides a potential long-term solution for patients but also positions Immusoft at the forefront of biotechnology in addressing rare and infectious diseases.

CytoVale, Inc. is a medical technology company based in San Francisco, California, established in 2012. The company specializes in developing biomarkers that leverage the mechanical properties of individual cells, a field known as mechanomics. By utilizing microfluidics technology, CytoVale can efficiently route and physically probe single cells to measure multiple biomarkers simultaneously. This innovative approach aims to enhance early detection of immune-mediated diseases, particularly sepsis, thereby improving patient outcomes and reducing treatment costs. CytoVale's integration of cell mechanics with machine learning positions it at the forefront of revolutionizing diagnostic practices in healthcare.

Quince Therapeutics is a preclinical stage biopharmaceutical company dedicated to developing innovative precision therapeutics for debilitating and rare diseases. The company has created a unique bone-targeting drug platform that enables the precise delivery of small molecules, peptides, or large molecules directly to the site of bone fractures and diseases. This targeted approach aims to enhance healing rates while minimizing off-target safety concerns often associated with non-targeted therapies. Quince Therapeutics focuses on addressing impairments related to strength, functionality, debilitating pain, and other serious health challenges.

Immusoft Corporation is a biotechnology company focused on developing an autologous cell therapy platform aimed at treating a range of human diseases through its proprietary Immune System Programming (ISP) technology. Founded in 2009 and based in Seattle, Washington, Immusoft specializes in modifying the DNA of a patient's immune cells to create biofactories capable of producing gene-encoded medicines, including essential proteins and enzymes that may be missing or defective. The company's innovative approach involves reprogramming B cells, a type of immune cell, which enables them to manufacture and secrete various antibodies. This process not only provides a potential long-term solution for patients but also positions Immusoft at the forefront of biotechnology in addressing rare and infectious diseases.

3Scan, Inc. specializes in developing advanced microscopy tools and software for automated tissue sectioning and imaging, primarily aimed at enhancing large-scale sample analysis and 3D visualizations. Founded in 2010 and based in San Francisco, California, the company focuses on addressing diseases that manifest at the tissue level, including cancer, heart disease, and neurodegenerative disorders. By integrating automation, machine learning, and computer vision, 3Scan's technology enables researchers and medical professionals to achieve greater throughput, improved quantification, and extensive image analysis compared to traditional histopathology methods. This data-driven approach aims to deepen the understanding of tissue biology, facilitating the discovery of new diagnostics and therapeutics. 3Scan was acquired by Transcriptic, Inc. in 2019.

Modern Meadow, LLC is a biofabrication company based in Brooklyn, New York, founded in 2011. The company specializes in creating animal-free leather from living cells, utilizing its proprietary Bio-Alloy and Bio-Farm technology platforms. These innovations leverage tuned proteins to produce sustainable materials that eliminate the need for petrochemical and animal-derived inputs while maintaining high performance. Modern Meadow’s products are designed for seamless integration into existing infrastructures across various industries, including materials and beauty. The company emphasizes lab-to-brand traceability, ensuring that its offerings are fully transparent throughout the production process. By focusing on fermentation-based bio-collagen and lightweight materials, Modern Meadow aims to significantly reduce greenhouse gas emissions and promote sustainability without compromising quality or appearance.